Classys Inc, a global aesthetics manufacturer based in South Korea, released its latest annual report, outlining its cumulative installed base and business structure across international markets.
According to the report, Classys operates in more than 80 countries worldwide and has reached a cumulative installed base of over 45,000 platforms, reflecting its expanding presence in the global medical aesthetics market.
The global medical aesthetics market is evolving, with strong demand continuing for injectable-based procedures led by companies such as Galderma. At the same time, growing attention is being directed toward energy-based treatments, as both providers and patients increasingly seek options that support more natural-looking outcomes.
Classys' business model is structured around continuous device utilization, enabling Mmdical aesthetic practices to operate equipment efficiently while maintaining long-term stability.
This model naturally supports recurring revenue, as consumables such as cartridges and tips are used repeatedly after initial platform installation.
As a result, consumables accounted for 46% of total revenue in 2025, while Ultraformer (HIFU) procedures performed using Classys devices exceeded 5.5 million worldwide last year. Additionally, Classys maintains an operating margin exceeding 50%, reflecting the strength of its platform-driven revenue structure and global expansion strategy.
Industry participants note that Classys continues to strengthen its position in the global medical aesthetics market, driven by a combination of high growth and strong profitability. The company reports a revenue guidance of approximately KRW 490 billion, representing 45% year-over-year growth
Within the medical device industry, companies achieving both high revenue growth and high profitability remain relatively rare, further highlighting investor interest in Classys' business model.
